Tempus AI (NASDAQ:TEM) Trading 6.3% Higher – Here’s Why

Tempus AI, Inc. (NASDAQ:TEM)’s share price traded up 6.3% during trading on Thursday . The company traded as high as $58.51 and last traded at $53.97. 8,464,662 shares traded hands during trading, a decline of 10% from the average session volume of 9,355,592 shares. The stock had previously closed at $50.77.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Loop Capital decreased their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Finally, Bank of America upped their target price on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.36.

Tempus AI Stock Performance

The firm’s fifty day moving average is $44.11 and its 200-day moving average is $47.97. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Transactions at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 187,655 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the completion of the transaction, the chief executive officer now directly owns 9,557,283 shares of the company’s stock, valued at $358,780,403.82. The trade was a 1.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. This represents a 2.39 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862,758 shares of company stock worth $79,585,675.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently bought and sold shares of TEM. First Horizon Advisors Inc. purchased a new stake in shares of Tempus AI in the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC purchased a new position in Tempus AI during the 4th quarter worth $67,000. Vestor Capital LLC purchased a new stake in shares of Tempus AI in the third quarter valued at about $153,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Tempus AI during the fourth quarter worth about $178,000. Finally, Stifel Financial Corp purchased a new position in shares of Tempus AI during the third quarter worth about $218,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.